Loading
No insider purchase over the last 90 days. The latest, by Anthon Jahreskog, was filed 04 Mar 2024.
Infant Bacterial Therapeutics is a listed company. Filings by its managers are published through Finansinspektionen. Nothing new has been filed by managers of Infant Bacterial Therapeutics in twelve months, the latest record being from 31 May 2024.
Over the whole record (from 2017), the tally stands at 47 purchases and 3 sales.
These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
25 of 58 declarations
Infant Bacterial Therapeutics is a company focused on developing treatments for bacterial diseases in infants. It is listed on the XSTO stock exchange.